Lexicon Pharmaceuticals (LXRX) Misses Q1 View By 3c
More News related to LXRX
- Thomas Weisel Starts Lexicon (LXRX) at Overweight, $2.50 Price Target
- Lexicon Pharma (LXRX) to Present LX1031 Phase 2 Results at GASTRO 2009
- Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
- Morning Movers 11/13: CNIC, TSTC, NLST, AGO, SLI Higher; LIME, GMET, BIOF, DISK, MRGE, SSY Lower
- After-Hours Movers 11/12: TSTC, LXRX, MDSO Higher; DISK, MRNA, LIME, BBI, ESE, JWN Lower
More News related to Earnings
- After-Hours Movers 12/03: LAVA, MRVL, FLOW, NX, AVGO Higher; TTWO, VSNT, SWHC, ZIOP, MENT, WES Lower
- Trading Radar for 12/4: Big Lots (BIG), Royal Bank of Canada (RY), Sirona Dental (SIRO) Report
- Unusual 11 Mid-Day Movers 12/03: ICOC, KTCC, CCRT, FFHL Higher; GRH, RSCR, ALOY, ARO Lower
- Notable Analyst Rating Changes 12/03: BAC, BKD, AVB, THC, RIG Upgraded; KIM, GENZ, REG, TCK Downgraded
- Notable Midday ETF Movers 12/3: EWJ, TUR Up; UNG, OIH, GDX Down
Lexicon Pharmaceuticals (Nasdaq: LXRX) reports Q1 LOSS of $0.16, 3 cents below the analyst estimate of ($0.13). Revenue for the quarter was $4.2 million, versus the consensus of $5.96 million.
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team.
Related Categories
EarningsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
